Loading provider…
Loading provider…
Neurology Physician in Mc Lean, VA
NPI: 1073703096Primary Employer
Mgmc, LLC
mgmcltd.co.uk
HQ Phone
Get MD Jessica's Phone NumberMobile
Get MD Jessica's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
DC State Medical License
DC State Medical License
2009 - 2026
VA State Medical License
2010 - 2026
MD State Medical License
2015 - 2024
NY State Medical License
2005 - 2010
PA State Medical License
2008 - 2009

American Board of Psychiatry and Neurology
Neurology

UCNS
Headache Medicine
Renaissance School of Medicine at Stony Brook University
stonybrook.edu
Medical School
Until 2004
NYU Grossman School of Medicine
med.nyu.edu
Residency • Neurology
2005 - 2008
NYU Grossman Long Island School of Medicine
Internship • Internal Medicine
2004 - 2005
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 69 | 119 |
| 2 | 64615Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 46 | 147 |
| 3 | J0585Injection, onabotulinumtoxina, 1 unit | 41 | 23,280 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 20 | 25 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 15 | 15 |
Authors: Michael Marmura, Jennifer Mcvige, Jennifer Robblee
Journal: J Headache Pain
Publication Date: 2024-03-11
Rimegepant safety and patient-reported outcomes among triptan-naïve, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study.
Authors: Jessica Ailani, Jelena Pavlovic, Glenn Pixton, Terence Fullerton
Publication Date: 2025-07-09
Lead Sponsor: Theranica
Intervention / Treatment: DEVICE: Nerivio Migra neurostimulation, DEVICE: Sham Nerivio Migra
Lead Sponsor: Satsuma Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: Dihydroergotamine
Lead Sponsor: Zosano Pharma Corporation
Intervention / Treatment: DRUG: Placebo, DRUG: C213 Microneedle System